Luis Borges, PhD

Dr. Borges was most recent­ly Chief Sci­en­tif­ic Offi­cer at Cen­tu­ry Ther­a­peu­tics, where he suc­cess­ful­ly built a mul­ti­func­tion­al dis­cov­ery and trans­la­tion­al research orga­ni­za­tion. Pri­or to Cen­tu­ry, he served as Chief Sci­en­tif­ic Offi­cer at Cell Med­ica, Senior Vice Pres­i­dent of Research at Five Prime Ther­a­peu­tics, and Sci­en­tif­ic Direc­tor in Amgen’s Ther­a­peu­tic Inno­va­tion Unit. Dr. Borges brings sci­en­tif­ic and oper­a­tional rig­or and decades of expe­ri­ence in drug devel­op­ment. This includes both dis­cov­ery research and trans­la­tion­al sci­ence, hav­ing helped to advance mul­ti­ple drug devel­op­ment can­di­dates from IND fil­ing into clin­i­cal devel­op­ment and onward through FDA approval. 

In his role at Metageno­mi, Dr. Borges will over­see the dis­cov­ery and sys­tem­at­ic advance­ment of the Com­pa­ny’s next-gen­er­a­­tion gene edit­ing tech­nolo­gies to accel­er­ate their path­way to clin­i­cal trans­la­tion for in vivo and ex vivo appli­ca­tions. Dr. Borges holds a Ph.D. in pathol­o­gy from the Uni­ver­si­ty of Wash­ing­ton School of Medicine.